It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.

[2] The results did not support further effort by the company.

[1] NS-2359 was also in clinical trials for the treatment of ADHD,[3] phase II having been completed in 2007.

[4] A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.

[5] This drug article relating to the nervous system is a stub.